Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1158-1165

  Odai, Tsuyoshi ^a   Matsunawa, Mizuho ^a   Takahashi, Ryo ^a   Wakabayashi, Kuninobu ^a   Isozaki, Takeo ^a   Yajima, Nobuyuki ^a   Miwa, Yusuke ^a   Kasama, Tsuyoshi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Infliximab; Rheumatoid arthritis; Tumor necrosis factor chemokine inhibitor

Indexed keywords

C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INFLIXIMAB; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;

ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHEMOKINE CX3CL1; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67149138450     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.081074     Document Type: Article

References (43)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361 (Pubitemid 40852711)
2. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207-229 (Pubitemid 30216034)
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-196
4. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712 (Pubitemid 44244541)
5. Gerard C, Rollins BJ. Chemokines and disease. Nature Immunol 2001;2:108-115
6. Kunkel SL, Lukacs NW, Kasama T, Strieter RM. The role of chemokines in inflammatory joint disease. J Leukocyte Biol 1996;58:6-12. (Pubitemid 26054588)
7. Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 2002;323:171-180 (Pubitemid 34651586)
8. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann Rheum Dis 2004;63:1186-1194
9. Chen X, Oppenheim JJ, Howard OM. Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol 2004;1:336-342
10. Szekanecz Z, Szucs G, Szanto S, Koch AE. Chemokines in rheumatic diseases. Curr Drug Targets 2006;7:91-102.
11. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
12. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-346
13. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-920
14. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
15. Yajima N, Kasama T, Isozaki T, et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: Potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005;52:1670-1675 (Pubitemid 40852874)
16. Kasama T, Isozaki T, Odai T, et al. Expression of angiopoietin-1 in osteoblasts and its inhibition by tumor necrosis factor-alpha and interferon-gamma. Transl Res 2007;149:265-273 (Pubitemid 46635316)
17. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999;163:1521-1528 (Pubitemid 29352775)
18. Braun-Moscovici Y, Markovits D, Zinder O, et al. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:497-500. (Pubitemid 43334571)
19. Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N, Giron-Gonzalez JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. J Rheumatol 2005;32:2102-2108 (Pubitemid 41587852)
20. Kageyama Y, Takahashi M, Torikai E, et al. Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:505-509 (Pubitemid 46359288)
21. Pittoni V, Bombardieri M, Spinelli FR, et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively downregulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002;61:723-725 (Pubitemid 34787711)
22. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 2007;27:467-472 (Pubitemid 46294986)
23. Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1088-1093 (Pubitemid 46863950)
24. McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol 2001;47:619-635
25. Edrees AF, Misra SN, Abdou NI. Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol 2005;23:469-474 (Pubitemid 41447616)
26. Chapman GA, Moores KE, Gohil J, et al. The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 2000;392:189-195 (Pubitemid 30184908)
27. Furuichi K, Wada T, Iwata Y, et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 2001;87:314-320 (Pubitemid 32260831)
28. Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO. Fractalkine expression in human renal inflammation. J Pathol 2002;196:85-90. (Pubitemid 34071583)
29. Bjerkeli V, Damas JK, Fevang B, Holter JC, Aukrust P, Froland SS. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis: possible role in vascular inflammation. Rheumatology 2007;46:1422-1427 (Pubitemid 47317087)
30. Matsunawa M, Isozaki T, Odai T, et al. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006;54:3408-3416 (Pubitemid 44737151)
31. Cardillo C, Schinzari F, Mores N, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 2006;80:275-281 (Pubitemid 44313905)
32. Klimiuk PA, Sierakowski S, Domyslawska I, Fiedorczyk M, Chwiecko J. Reduction of soluble adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor levels in serum of rheumatoid arthritis patients following multiple intravenous infusions of infliximab. Arch Immunol Ther Exp (Warsz) 2004;52:36-42. (Pubitemid 39317969)
33. Strunk J, Bundke E, Lange U. Anti-TNF-alpha antibody infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 2006;26:252-256 (Pubitemid 41830984)
34. Ruth JH, Volin MV, Haines GK 3rd, et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001;44:1568-1581
35. Volin MV, Woods JM, Amin MA, Connors MA, Harlow LA, Koch AE. Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am J Pathol 2001;159:1521-1530 (Pubitemid 32947980)
36. Blaschke S, Koziolek M, Schwarz A, et al. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 2003;30:1918-1927. (Pubitemid 37075537)
37. Nanki T, Urasaki Y, Imai T, et al. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. J Immunol 2004;173:7010-7016 (Pubitemid 39541090)
38. Aries PM, Lamprecht P, Gross WL. Biological therapies: new treatment options for ANCA-associated vasculitis? Exp Opin Biol Ther 2007;7:521-533
39. Lin J, Ziring D, Desai S, et al. TNF-alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008;126:13-30. (Pubitemid 350266448)
40. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-530 (Pubitemid 27508241)
41. Nanki T, Imai T, Nagasaka K, et al. Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2878-2883 (Pubitemid 35315878)
42. Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM. Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum 2007;56:2512-2522 (Pubitemid 47237270)
43. Vis M, Bos WH, Wolbink G, et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. J Rheumatol 2008;35:425-428